WO2004009557A1 - 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors - Google Patents
6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors Download PDFInfo
- Publication number
- WO2004009557A1 WO2004009557A1 PCT/US2003/022401 US0322401W WO2004009557A1 WO 2004009557 A1 WO2004009557 A1 WO 2004009557A1 US 0322401 W US0322401 W US 0322401W WO 2004009557 A1 WO2004009557 A1 WO 2004009557A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- carbon atoms
- halogen
- Prior art date
Links
- 0 *c1n[n](*)c2c1ccc(N(*)*)c2 Chemical compound *c1n[n](*)c2c1ccc(N(*)*)c2 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates generally to the field of phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, e.g., aminoindazole and aminobenzofuran analogs, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- novel compounds e.g., aminoindazole and aminobenzofuran analogs
- the cyclic nucleotide specific phosphodiesterases represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in termination of their messenger role.
- PDEs cyclic nucleotide specific phosphodiesterases
- PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, cahnodulin or cGMP, and their selective inhibition by various compounds.
- PDE 1 is stimulated by Ca /cahnodulin.
- PDE 2 is cGMP-dependent, and is found in the heart and adrenals.
- PDE 3 is cGMP-dependent, and inhibition of this enzyme creates positive inotropic activity.
- PDE 4 is cAMP specific, and its inhibition causes airway relaxation, antiinflammatory and antidepressant activity.
- PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
- PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs.
- the PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See: Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320- 324 (1997)]
- PDE4A PDE4A
- PDE4B PDE4C
- PDE4D PDE4D
- PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5'-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory. Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and ariflo are powerful antiinflammatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms.
- cAMP and cGMP are second messengers that mediate cellular responses to many different hormones and neurotransmitters. Thus, therapeutically significant effects may result from PDE inhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as those located in the nervous system and elsewhere in the body.
- Rolipram previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes.
- Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia, [see "The PDE IV Family Of Calcium- Phosphodiesterases Enzymes," John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799- 807 for a general review). Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds.
- the primary side effect in primates is emesis, while the primary side effects in rodents are testicular degranulation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion.
- the present invention relates to novel compounds, e.g., aminoindazole and aminobenzofuran analogs, that inhibit PDE4 enzymes, and especially have improved side effect profiles, e.g., are relatively non-emetic, (e.g., as compared to the previously discussed prior art compounds).
- the compounds selectively inhibit PDE4 enzymes.
- the compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system.
- the present invention provides methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, e.g., mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such memory impairment may be improved by effectively inhibiting PDE4 enzyme activity.
- a patient e.g., mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to catabolism of intracellular cAMP levels by PDE 4 enzymes
- the compounds of the invention improve such diseases by inhibiting PDE4 enzymes at doses which do not induce emesis.
- the present invention includes compounds of Formulas I and II:
- R 1 is H, alkyl having 1 to 8 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl), or a heterocyclic group, which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoal
- R 3 is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, cyano, d- 4 -alkoxy, or combinations thereof (e.g., methyl, ethyl, propyl, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion which is branched or unbranched has 1 to 5 carbon atoms, and which is unsubstituted or substituted in the carbocyclic portion one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof, and the alkyl portion is optionally substituted by halogen, C 1 - 4 -alkoxy, cyano or combinations thereof (e.g., cyclohexenylmethyl, etc.), arylalky
- R 5 -L- or combinations thereof (e.g., substituted or unsubstituted phenyl, naphthyl, and biphenyl, such as phenyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl, dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl, etc.), or heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino,
- R 5 -L- tert-butyldimethylsilyloxy
- R 5 -L- or combinations thereof (e.g., pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.); is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times with halogen, C ⁇ - 4 -alkyl, ⁇ -alkoxy, oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.), alkylamino or dialkylamino wherein each alkyl portion has independently 1 to 8, preferably 1 to 4 carbon atoms (e.g., dimethylamino, etc.), a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon
- L is a single bond or a divalent aliphatic radical having up to 8 carbon atoms wherein one or more -CH 2 - groups are each optionally replaced by -O-, -S-, -SO -, -SO-, -NR 6 -, - SO 2 NH-, -NHSO 2 -, -CO-, -NR 6 CO-, -CONR 6 -, -NHCONH-, -OCONH, -NHCOO-, - SCONH-, -SCSNH-, or -NHCSNH- (e.g.,-O-, CH 2 -, -CO-, -CO-O-, -O-CO-, -CO-NH-, - NH-CO-, -CH 2 CH 2 CH 2 -NH-CO-, -CH 2 -CH 2 -O-, -SO 2 -NH-CH 2 CH 2 -O-, -O-CH 2 CH 2 -O-,
- R 6 is H, alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times with halogen, C 1 - 4 -alkyl, Cr 4 - alkoxy, oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.);
- R is alkoxy or alkylthio, in each case having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.),
- R is -CO-C 1- -alkyl which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF , etc.), or is
- R 9 is H or alkyl having 1 to 4 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH , CHF 2 , CF 3 , etc.)
- R 10 is alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF , CF 3 , etc.)
- R 11 is alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF , CF 3 , etc.)
- X and Y are each independently O or S
- A is alkylene having 2 to 7 carbon atoms which is unsubstituted or substituted one or more times by halogen
- R , R , R , R and R are as defined above.
- the compounds of this subgenus of Formulae I and II not only have PDE4 inhibitory activity, but also are useful as intermediates for preparing compounds of Formula II in which R 3 and R 4 are both other than H.
- preferred compounds of Formulas I and II are those of subformulas V and VI
- R , R , R , R and R are as defined in Formulas I and II and one of B, D and E is N and the others are C.
- D is N.
- R 4 is preferably pyridyl or phenyl which in each case is substituted or unsubstituted.
- the compounds of formulas I and II are selected from the following compounds: 7-Methoxy-2-(2-methyl-( 1 ,3-dioxolane-2-yl))-4-[N-(4-pyridylmethyl)] aminobenzofuran,
- optically active compounds can be in the form of their separate enantiomers or mixtures thereof, including racemic mixtures.
- the compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, e.g., mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia.
- intermediate compounds which correspond to compounds of Formulas I and II, wherein R 2 , R 3 , R 4 and R 8 are as previously defined for Formulas I and II, but R or R is H, tert-butyldimethylsilyl-, or a suitable phenolic or indazolyl protecting group.
- Suitable protecting groups are described, for example, in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd Edition, John Wiley & Sons, 1999, pp. 246-293.
- radio-labeled compounds such as where R 7 is 3 H 3 CO-, 2 H 3 CO-, 14 CH - or ⁇ CH 3 -, for example by removing the protecting group and reacting the resultant compound in which R 1 or R 7 is H with suitable radio-labeled reagents.
- radio-labeled compounds are useful for determining compound tissue distribution in animals, in PET imaging studies, and for in vivo, ex vivo, and in vitro binding studies.
- Halogen herein refers to F, CI, Br, and I. Preferred halogens are F and CI.
- Alkyl as a group or substituent per se or as part of a group or substituent (e.g., alkylamino, trialkylsilyloxy, aminoalkyl, hydroxyalkyl), means a straight-chain or branched- chain aliphatic hydrocarbon radical having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms.
- Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl.
- alkyl groups include 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2- dimethylpropyl, 1-ethylpropyl, 1-, 1-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3- dimethylbutyl, 1- or 2-ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl/ ethylmethylbutyl, dimethylbutyl, and the like.
- Substituted alkyl groups are alkyl groups as described above which are substituted in one or more positions by halogens, oxo, hydroxyl, C 1-4 -alkoxy and or cyano.
- Halogens are preferred substiruents, especially F and CI.
- Alkoxy means alkyl-O- groups and alkoxyalkoxy means alkyl-O-alkyl-O- groups in which the alkyl portions are in accordance with the previous discussion.
- Suitable alkoxy and alkoxyalkoxy groups include methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy methoxymethoxy ethoxymethoxy, propoxymethoxy, and methoxyethoxy.
- Preferred alkoxy groups are methoxy and ethoxy.
- alkoxycarbonyl means alkyl -O-CO- in which the alkyl portion is in accordance with the previous discussion. Examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and tert-butoxycarbonyl.
- Cycloalkyl means a monocyclic, bicyclic or tricyclic nonaromatic saturated hydrocarbon radical having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, especially 3 to 6 carbon atoms.
- Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, 1-decalin, adamant- 1-yl, and adamant-2-yl.
- Suitable cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, bicyclo[4.2.0]octyl, and spiro[3.5]nonyl.
- Preferred cycloalklyl groups are cyclopropyl, cyclopentyl and cyclohexyl.
- the cycloalkyl group can be substituted, for example, substituted by halogens and/or alkyl groups.
- Cycloalkylalkyl refers to cycloalkyl-alkyl radicals in which the cycloalkyl and alkyl portions are in accordance with previous discussions. Suitable examples include cyclopropylmethyl and cyclopentylmethyl.
- Aryl as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms.
- Suitable aryl groups include phenyl, naphthyl and biphenyl.
- Substituted aryl groups include the above-described aryl groups which are substituted one or more times by, for example, halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, dialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, and phenoxy.
- Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include benzyl, 1-phenethyl, 2- phenethyl, phenpropyl, phenbutyl, phenpentyl, and napthyhnethyl.
- Heteroaryl refers to an aromatic heterocyclic group having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is a heteroatom.
- the heteroaryl group contains 1 to 3, especially 1 or 2, hetero-ring atoms which are selected from N, O and S.
- Suitable heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithialyl, oxathialyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indolyl, isoindolyl, indazoly
- Substituted heteroaryl refers to the heteroaryl groups described above which are substitued in one or more places by, for example, halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino.
- Heterocycles include heteroaryl groups as described above as well as non-aromatic cyclic groups containing at least one hetero-ring atom, preferably selected from N, S and O, for example, tetrahydrofuranyl, piperidinyl, and pyrrolidinyl.
- Heterocycle-alkyl refers to a heterocycle-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, and isoquinolinylmethyl.
- Suitable examples are cyclopentenyl, cyclohexenyl, cyclohexadienyl, tetrahydronaphthenyl and indan-2-yl.
- Suitable alkenyl groups are ethenyl, 1-propenyl, 2-methylethenyl, 1-butene, 2-butene, 1- pentenyl, and 2-pentenyl.
- Alkynyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2 -CH 2 - structures are each replaced by -C ⁇ C-.
- Suitable alkynyl groups are ethynyl, propynyl, 1-butynyl, and 2-butynyl.
- Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms in which the alkyl portion can be substituted by halogen, alkyl, aryl and/or alkoxy, or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by, for example, halogen, alkyl and/or alkoxy.
- Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl.
- Substituted radicals preferably have 1 to 3 substiruents, especially 1 to 2 substituents.
- R 1 can be an alkyl group having preferably 2 to 4 carbon atoms which is optionally substituted by halogen, preferably fluorine or chlorine.
- R 1 can also preferably be cycloalkyl, particularly cyclopentyl or cyclohexyl.
- R 2 is preferably H or alkyl having 1 to 4 carbon atoms, especially C 2 H 5 .
- R 3 is preferably hydrogen, alkyl having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, or n-butyl), arylalkyl (e.g., substituted or unsubstitituted benzyl, phenethyl, and phenpropyl), or a heteroarylalkyl group (e.g., substituted or unsubstituted pyridylmethyl, furanylmethyl, thienylmethyl, pyrrolylmethyl, pyrimidinylmethyl, thiazolylmethyl, isoquinolinylmethyl and quinolinylmethyl).
- Preferred substituents for aryl and heteroaryl portions of R 3 are F, CI, CH 3 , C 2 H 5 , OCH 3; and CN.
- R is preferably pyridy
- R 4 is preferably aryl, or heteroaryl, especially phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, and isoquinolinyl, which in each case is unsubstituted or is substituted one or more times.
- Preferred substituents are OH, F, CI, CF 3 , alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl, CH OH, CONHOH, CONH 2 , methylenedioxy, COOH, and combinations thereof.
- R 4 can be phenyl substituted by halogen, COOH and/or CN.
- R 4 is aryl, especially, phenyl
- preferred substituents include R 5 -L-, e.g., R 5 -, R 5 -O-, R 5 -CO-, R 5 -NH-CO-, R 5 -SO 2 -NH-, R 5 -SO 2 -NH-alkylene-O-, NH 2 -alkyl-NH-CO-, R 5 -alkylene-NH-CO-, alkyl-CO-NH-alkyl- as well as methyl, ethyl, CI, F, CN, OCH 3 , CF 3 , amino, nitro, HOCH 2 and COOH.
- R 4 is aryl substituted by R 5 -SO 2 -NH- it is preferably a substituted phenyl group and R 5 is preferably methyl, ethyl, propyl or phenyl.
- R 4 is aryl substituted by R 5 -SO -NH-alkylene-O- it is preferably a substituted phenyl.
- R 5 is preferably methyl, ethyl, propyl or phenyl and alkylene is preferably -CH 2 -, -CH 2 CH 2 - or-CH 2 CH 2 CH 2 -.
- R 4 is aryl substituted by R 5 -L- it is preferably substituted phenyl.
- preferred R 5 groups include phenyl, tetrazolyl, oxazinyl, piperazinyl, methylpiperazinyl, pyridyl, methylpyridyl, pyrrolinyl, methylpyrrolinyl, piperadinyl, or methylpiperadinyl
- L is preferably a single bond, -O-, -CO-, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 -O-, -CH 2 CH 2 -O-, -CH 2 CH 2 CH 2 -O-, -CH 2 -NH-CH 2 CH 2 -O-, -CO-NH-, -NH-CO-, or -CONHSO 2 -.
- R 7 is preferably alkoxy having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, e.g., CH 3 or C 2 H 5 .
- R 8 is preferably -CO-C 1-4 -alkyl, e.g., -COCH 3 .
- R 9 is preferably -CH 3 .
- X and Y are preferably both O or S, especially O.
- A is preferably -CH 2 CH 2 -.
- preferred PDE4 inhibitors in accordance with the invention are compounds described by subformulas la to He which correspond to formulas I and II but exhibit the following preferred groups: la R is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted.
- lb R 1 is cycloalkyl;and
- R 2 is H or C 2 H 5 .
- Ic R 1 is cycloalkyl
- R 2 is H or C 2 H 5 ;
- R is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted;
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. Id R 1 is cyclopentyl; R 2 is H or C 2 H 5 ;
- R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted;
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted.
- Ie R 1 is cyclopentyl
- R 2 is H or C 2 H 5 ;
- R 3 is pyridyl which is substituted or unsubstituted
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted. If R 1 is cyclopentyl;
- R 2 is H or C 2 H 5 ;
- R is pyridyl which is substituted or unsubstituted
- R 4 is phenyl which is substituted or unsubstituted.
- Ila R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted.
- lib R 7 is alkoxy having 1 to 4 carbon atoms;
- R 8 is COCH 3 or
- R y is -CH 3 ;
- X and Y are both O or S; and A is -CH 2 CH 2 -.
- R 3 is arylalkyl or heteroarylalkyl, in each case substituted or unsubstituted; and R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted;
- R 7 is alkoxy having 1 to 4 carbon atoms;
- R 8 is COCH 3 or
- R 9 is -CH 3 ;
- X and Y are both O or S; and A is -CH 2 CH 2 -.
- lid R 3 is pyridyl which is substituted or unsubstituted;
- R 4 is H or is aryl or heteroaryl, in each case substituted or unsubstituted;
- R 7 is alkoxy having 1 to 4 carbon atoms;
- R 8 is COCH 3 or
- R 9 is -CH 3 ;
- X and Y are both O or S; and A is -CH 2 CH 2 -.
- R is alkoxy having 1 to 4 carbon atoms;
- R 8 is COCH 3 or
- R 9 is -CH 3 ;
- X and Y are both O or S;
- A is -CH 2 CH 2 -.
- Preferred aspects include pharmaceutical compositions comprising a compound of this invention and a pharmaceutically acceptable carrier and, optionally, another active agent as discussed below; a method of inhibiting a PDE4 enzyme, especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g., in an animal model, or in a mammal or in a human); a method of treating neurological syndrome, e.g., loss of memory, especially long-term memory, cognitive impairment or decline, memory impairment, etc. a method of treating a disease state modulated by PDE4 activity, in a mammal, e.g., a human, e.g., those mentioned herein.
- a method of inhibiting a PDE4 enzyme especially an isoenzyme, e.g., as determined by a conventional assay or one described herein, either in vitro or in vivo (in an animal, e.g.,
- the compounds of the present invention may be prepared conventionally. All starting materials are known or can be conventionally prepared from known starting materials. Some of the processes which can be used are described below.
- Starting material 6-amino-l-cyclopentyl-3-ethylindazole can be synthesized from the corresponding 6-carboxy-l-cyclopentyl-3-ethylindazole by a Curtius rearrangement.
- the starting 6-carboxy-l-cyclopentyl-3-ethylindazole can be prepared by methods common in the art (see, e.g., WO 098/09961).
- starting 6-amino-l-cyclopentyl-3-ethylindazoles can be synthesized by animation of 6-halo-l-cycloalkyl-3-ethylindazole or reduction of 6-nitro-l- cycloalkyl-3-ethylindazole.
- the indazole scaffold can be prepared by several methods common to the art, such as by reaction of cycloalkylhydrazine with 2,4-difluoropropiophenone.
- the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
- appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
- Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
- the optically active bases or acids are then liberated from the separated diastereomeric salts.
- a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers.
- Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
- Enzymatic separations, with or without derivitization, are also useful.
- the optically active compounds of Formulae I and II can likewise be obtained by chiral syntheses utilizing optically active starting materials.
- the compounds can be used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 3 H, ⁇ C and/or 14 C.
- the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts and prodrugs of all the compounds of the present invention.
- Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
- Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, mangnesium, ammonium, and choline salts.
- acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
- alkali and alkaline earth j metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
- acid salts that can be obtained by reaction with inorganic or organic acids: acetates, adipates, alginates, citrates, aspartates, benzoates, benzenesulfonates, bisulfates, butyrates, camphorates, digluconates, cyclopentanepropionates, dodecylsulfates, ethanesulfonates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, fumarates, hydrobromides, hydroiodides, 2-hydroxy-ethanesulfonates, lactates, maleates, methanesulfonates, nicotinates, 2-naphthalenesulfonates, oxalates, palmoates, pectinates, persulfates, 3-phenylpropionates, picrates, pivalates, propionates,
- the salts formed are pharmaceutically acceptable for administration to mammals.
- pharmaceutically unacceptable salts of the compoxinds are suitable as intermediates, for example, for isolating the compound as a salt and then converting the salt back to the free base compound by treatment with an alkaline reagent.
- the free base can then, if desired, be converted to a pharmaceutically acceptable acid addition salt.
- the compounds of the invention can be administered alone or as an active ingredient of a formulation.
- the present invention also includes pharmaceutical compositions of compounds of Formulas I or II containing, for example, one or more pharmaceutically acceptable carriers.
- the compounds of the present invention can be administered to anyone requiring or desiring PDE4 inhibition, and/or enhancement of cognition. Administration may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermally, and by ocular administration.
- solid oral dosage forms can be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
- the compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
- liquid oral dosage forms can also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
- dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
- the compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
- Suppositories for rectal administration of the compounds of the present invention can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
- a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
- Formulations for vaginal administration can be in the form of a pessary, tampon, cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
- the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
- Aerosol formulations suitable for administering via inhalation also can be made.
- the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions.
- the aerosol formulation can be placed into a pressurized acceptable propellant.
- the compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine). h such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below its usual dosage range.
- the present invention further includes methods of treatment that involve inhibition of PDE4 enzymes.
- the present invention includes methods of selective inhibition of PDE4 enzymes in animals, e.g., mammals, especially humans, wherein such inhibition has a therapeutic effect, such as where such inhibition may relieve conditions involving neurological syndromes, such as the loss of memory, especially long-term memory.
- Such methods comprise administering to an animal in need thereof, especially a mammal, most especially a human, an inhibitory amount of a compound, alone or as part of a formulation, as disclosed herein.
- the condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information.
- Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld- Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
- Dementias are diseases that include memory loss and additional intellectual impairment separate from memory.
- the present invention includes methods for treating patients suffering from memory impairment in all forms of dementia.
- Dementias are classified according to their cause and include: neurodegenerative dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular (e.g., infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld- Jacob Disease, multiple sclerosis, traumatic (e.g., subdural hematoma or traumatic brain injury), infectious (e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals, alcohol, some medications), metabolic (e.g., vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g., depression and schizophrenia), and hydrocephalus.
- neurodegenerative dementias e.g., Alzheimer's,
- the present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline.
- MCI mild cognitive impairment
- the present invention includes methods of treatment for memory impairment as a result of disease.
- the invention includes methods for dealing with memory loss resulting from the use of general anesthetics, chemotherapy, radiation treatment, post-surgical trauma, and therapeutic intervention.
- the compounds may be used to treat psychiatric conditions including schizophrenia, bipolar or manic depression, major depression, and drug addiction and morphine dependence. These compounds may enhance wakefulness.
- PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis. PDE4 inhibitors are also known to be anti- inflammatory. The combination of anti-apoptotic and anti-inflammatory properties make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, neuro genesis, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA).
- ALS amylolaterosclerosis
- MSA multiple systems atrophy
- the present invention includes methods of treating patients suffering from memory impairment due to, for example, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld- Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions including acute neuronal diseases, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound according to Formula I or II or pharmaceutically acceptable salts thereof.
- the compounds of the present invention can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia.
- the compounds can also be used to treat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders.
- the compounds of the invention also exhibit anti-inflammatory activity.
- inventive compounds are useful in the treatment of a variety of allergic and inflammatory diseases, particularly disease states characterized by decreased cyclic AMP levels and/or elevated phosphodiesterase 4 levels.
- a method of treating allergic and inflammatory disease states comprising administering an effective amount of a compound according to Formulas I or II or a pharmaceutically acceptable salt thereof.
- Such disease states include: asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid ( spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema
- PDE4 inhibitors for treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor are known within the art. See, e.g., WO 98/58901, JP-11-18957, JP 10-072415, WO 93/25517, WO 94/14742, US 5,814,651, and US 5,935,9778. These references also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds. The entire disclosures of these documents are hereby incorporated by reference.
- PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for treatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis (RA), for long-term inhibition of mesenchymal-cell proliferation after transplantation, for treatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for treatment of B cell chronic lymphocytic leukemia (B-CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemia-reperfusion injury (IRI) , for corneal hydration , for inhibition of IL-2R expression and thereby abolishing HIV-1 DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and treatment of colitis, and to inhibit mast cell degranulation.
- RA rheumatoid arthritis
- RA rheumatoid arthritis
- RA rhe
- the compoxinds of the present invention can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine).
- each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
- the dosages of the compounds of the present invention depend upon a variety of factors including the particular syndrome to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, pharmacokinetic profile of the compound, and the presence of any deleterious side-effects, among other considerations.
- the compounds of the invention are typically administered at dosage levels and in a mammal customary for PDE4 inhibitors such as those known compounds mentioned above.
- the compounds can be administered, in single or multiple doses, by oral administration at a dosage level of, for example, 0.01-100 mg/kg/day, preferably 0.1-70 mg/kg/day, especially 0.5-10 mg/kg/day.
- Unit dosage forms can contain, for example, 0.1-50 mg of active compound.
- the compounds can be administered, in single or multiple dosages, at a dosage level of, for example, 0.001-50 mg/kg/day, preferably 0.001-10 mg/kg/day, especially 0.01-1 mg/kg/day.
- Unit dosage forms can contain, for example, 0.1-10 mg of active compound.
- the reaction mixture was diluted with EtOAc and washed twice with H 2 O and extracted with 3 x 15 mL of 3NHC1.
- the combined acid extracts were washed with 15 mL of EtOAc and then carefully neutralized with 6N ⁇ aOH to pH greater than 12.
- the basic solution was extracted with 2 15 mL of EtOAc and the combined organic fractions were subsequently washed with 15 mL of H O and brine, dried (MgSO ), and concentrated.
- the residue was purified by chromatography over silica gel (Biotage Flash 40M) eluting with 25% EtOAc in hexanes.
- Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme.
- the cDNA encoding hPDE-4D6 was subcloned into a baculovirus vector.
- Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was expressed.
- the baculo virus-infected cells were lysed and the lysate was used as source of hPDE- 4D6 enzyme.
- the enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cDNA encoding other PDE-4 enzymes.
- Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to 5'- adenosine monophosphate (5 '-AMP).
- Nucleotidase converts 5 '-AMP to adenosine. Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine.
- Adenosine is readily separated from cAMP by neutral alumina columns.
- Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine.
- Cell lysates (40 ul) expressing UPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature. Final concentrations of assay components were: 0. 4 ug enzyme, lOmM Tris-HCl (pH 7.5), lOmM MgCl 2 , 3 uM cAMP, 0.002
- test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concentration of DMSO is 0.1%. DMSO does not affect enzyme activity at this concentration. A decrease in adenosine concentration is indicative of inhibition of PDE activity.
- pIC 50 values were determined by screening 6 to 12 concentrations of compound ranging from 0.1 nM to 10,000 nM and then plotting drug concentration versus 3 H-adenosine concentration. Nonlinear regression software (Assay Explorer ® ) was used to estimate pIC 5 o values.
- the test was performed as previously described (Zhang, H.-T., Crissman, A.M., Dorairaj, N.R., Chandler, L.J., and O'Donnell, J.M., Neuropsychopharmacology, 2000, 23, 198-204.).
- the apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, PA) consisted of a two- compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door.
- the floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source. All experimental groups were first habituated to the apparatus the day before the start of the experiment.
- the rat (Male Spraque-Dawley (Harlan) weighing 250 to 350 g) was placed in the illuminated compartment facing away from the closed guillotine door for 1 minute before the door was raised. The latency for entering the darkened compartment was recorded. After the rat entered the darkened compartment, the door was closed and a 0.5 mA electric shock was administered for 3 seconds. Twenty-four hours later, the rat was administered 0.1 mg/kg MK-801 or saline, 30 minutes prior to the injection of saline or test compound (dosed from 0.1 to 2.5 mg/kg, i.p.), which was 30 minutes before the retention test started. The rat was again placed in the illuminated compartment with the guillotine door open.
- the latency for entering the darkened compartment was recorded for up to 180 seconds, at which time the trial was terminated. All data were analyzed by analyses of variance (ANOVA); individual comparisons were made using Kewman-Keuls tests. Na ⁇ ve rats required less than 30 seconds, on average, to cross from the illuminated compartment to the darkened compartment. However, 24 hours after the electric shock exposure, most rats pretreated with vehicle did not re-enter the darkened compartment; the average latency was increased up to 175 seconds (p ⁇ 0.001). Pretreatment with MK-801 (0.1 mg/kg) markedly reduced this latency when compared to the vehicle (p ⁇ 0.001). This amnesic effect of MK-801 is reversed in a statistically significant manner by actual test compounds in a dose-dependent fashion.
- mice Male Spraque-Dawley (Harlan) weighing 250 to 350 g were placed in the eight-arm radial maze (each arm was 60x10x12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days.
- Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each. The rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first.
- test duration i.e., the time spent in the collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests. MK-801 or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues.
- MK-801 0.1 mg/kg, i.p.
- MK-801 0.1 mg/kg, i.p.
- This amnesic effect of MK- 801 on working memory is reversed in a statistically significant manner by the administration of actual test compounds in a dose-dependent fashion.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003256601A AU2003256601B2 (en) | 2002-07-19 | 2003-07-18 | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
EP03765684A EP1549619B1 (en) | 2002-07-19 | 2003-07-18 | 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
BR0313000-2A BR0313000A (en) | 2002-07-19 | 2003-07-18 | Compounds, pharmaceutical composition and method for inhibiting pde4 enzyme, enhancing cognition and / or treating psychosis in a patient |
DE60325984T DE60325984D1 (en) | 2002-07-19 | 2003-07-18 | 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE-4 INHIBITORS |
MXPA05000825A MXPA05000825A (en) | 2002-07-19 | 2003-07-18 | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors. |
NZ537725A NZ537725A (en) | 2002-07-19 | 2003-07-18 | 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
CA002492911A CA2492911A1 (en) | 2002-07-19 | 2003-07-18 | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
JP2004523528A JP2006502995A (en) | 2002-07-19 | 2003-07-18 | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
IL16616405A IL166164A0 (en) | 2002-07-19 | 2005-01-05 | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
HR20050082A HRP20050082A2 (en) | 2002-07-19 | 2005-01-26 | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
NO20050871A NO20050871L (en) | 2002-07-19 | 2005-02-18 | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
HK06101282A HK1081194A1 (en) | 2002-07-19 | 2006-01-27 | 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof |
AU2010200233A AU2010200233A1 (en) | 2002-07-19 | 2010-01-21 | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39672602P | 2002-07-19 | 2002-07-19 | |
US60/396,726 | 2002-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004009557A1 true WO2004009557A1 (en) | 2004-01-29 |
Family
ID=30770939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/022401 WO2004009557A1 (en) | 2002-07-19 | 2003-07-18 | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
Country Status (20)
Country | Link |
---|---|
US (2) | US7655802B2 (en) |
EP (1) | EP1549619B1 (en) |
JP (1) | JP2006502995A (en) |
CN (2) | CN100381425C (en) |
AT (1) | ATE421505T1 (en) |
AU (2) | AU2003256601B2 (en) |
BR (1) | BR0313000A (en) |
CA (1) | CA2492911A1 (en) |
CO (1) | CO5680420A2 (en) |
DE (1) | DE60325984D1 (en) |
ES (1) | ES2323688T3 (en) |
HK (1) | HK1081194A1 (en) |
HR (1) | HRP20050082A2 (en) |
IL (1) | IL166164A0 (en) |
MX (1) | MXPA05000825A (en) |
NO (1) | NO20050871L (en) |
NZ (1) | NZ537725A (en) |
RU (1) | RU2354648C2 (en) |
WO (1) | WO2004009557A1 (en) |
ZA (1) | ZA200500436B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007519684A (en) * | 2004-02-02 | 2007-07-19 | ノバルティス アクチエンゲゼルシャフト | Coupling reactions useful in the preparation of (1H-tetrazol-5-yl) -biphenyl derivatives |
JP2008542332A (en) * | 2005-05-31 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pharmaceutical composition for the treatment of respiratory diseases |
WO2009025478A1 (en) | 2007-08-17 | 2009-02-26 | Lg Life Sciences Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
US8017641B2 (en) | 2003-03-03 | 2011-09-13 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
US8039639B2 (en) | 2006-01-31 | 2011-10-18 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
WO2014072881A1 (en) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8803881B2 (en) * | 2007-09-26 | 2014-08-12 | Autodesk, Inc. | Navigation system for a 3D virtual scene |
BRPI0722181A2 (en) * | 2007-11-30 | 2014-04-08 | Yu Fen Chi | "ANTIMELANCOLIC MEDICINAL PRODUCT PREPARED WITH JUJUBA CAMP-BASED MATERIALS" |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000868A1 (en) * | 1995-06-21 | 1997-01-09 | Sanofi | 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
WO1997049702A1 (en) * | 1996-06-25 | 1997-12-31 | Pfizer Inc. | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
WO1998009961A1 (en) * | 1996-09-04 | 1998-03-12 | Pfizer Inc. | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
WO2000069841A2 (en) * | 1999-05-17 | 2000-11-23 | Bayer Aktiengesellschaft | Benzofuranylaminoalcohols |
JP2001011047A (en) * | 1999-06-28 | 2001-01-16 | Nikken Chem Co Ltd | Phosphodiesterase inhibitor |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE580519C (en) * | 1932-02-26 | 1933-07-12 | I G Farbenindustrie Akt Ges | Process for the preparation of 2-oxy-3-arylaminonaphthalenes |
US3259623A (en) | 1963-06-14 | 1966-07-05 | Olin Mathieson | Process for preparing 2-(secondary amino)-halogenopyrimidines |
GB1337389A (en) | 1969-12-10 | 1973-11-14 | Ici Ltd | Pyrimidine derivatives |
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
FR2244520B1 (en) | 1973-07-06 | 1977-02-04 | Ugine Kuhlmann | |
US4524373A (en) | 1982-02-24 | 1985-06-18 | Kanzaki Paper Manufacturing Co., Ltd. | Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material |
GB2202434B (en) * | 1987-03-25 | 1990-03-28 | Tachi S Co | Apparatus for manufacturing a seat |
US5221682A (en) * | 1989-06-28 | 1993-06-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Heteroarylamino- and heteroaryloxypyridinamines and related compounds |
GB9311281D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
US5935978A (en) | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5204226A (en) | 1991-03-04 | 1993-04-20 | International Business Machines Corporation | Photosensitizers for polysilanes |
US5204366A (en) | 1991-06-10 | 1993-04-20 | American Cyanamid Company | 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof |
US6096768A (en) | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
AU670949B2 (en) | 1992-06-15 | 1996-08-08 | Celltech Limited | Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors |
US5679696A (en) | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
PL307265A1 (en) | 1992-07-28 | 1995-05-15 | Rhone Poulenc Rorer Ltd | Compounds containing a phenyl group bonded with aryl or heteroaryl group through their bonding aliphatic group or that containing heteroatom |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
TW263495B (en) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
JPH09501405A (en) | 1993-05-27 | 1997-02-10 | スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク | N-substituted 3-benzazepines or isoquinolines for antiarrhythmia |
EP0706513B1 (en) | 1993-07-02 | 2002-05-15 | Byk Gulden Lomberg Chemische Fabrik GmbH | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
JPH07206789A (en) | 1993-09-01 | 1995-08-08 | Taisho Pharmaceut Co Ltd | Production of combretastatin analog compound |
BR9407799A (en) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composition of matter treatment method and pharmaceutical composition |
ATE260911T1 (en) | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | TRISUBSUTITUTED PHENYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PHOSPHODIESTERASE (TYPE IV) INHIBITORS |
GB9326600D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
FR2729142A1 (en) | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | New heterocyclic amine derivs. |
US5731477A (en) | 1995-01-31 | 1998-03-24 | Smithkline Beecham Corporation | Method for synthesis of aryl difluoromethyl ethers |
IT1275433B (en) | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | DIARYLDIAMINE DERIVATIVES |
US5728712A (en) | 1995-05-19 | 1998-03-17 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5710170A (en) | 1995-12-15 | 1998-01-20 | Merck Frosst Canada, Inc. | Tri-aryl ethane derivatives as PDE IV inhibitors |
GB9603723D0 (en) | 1996-02-22 | 1996-04-24 | Merck & Co Inc | Diphenyl pyridyl derivatives as pde iv inhibitors |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
US6235736B1 (en) | 1997-06-24 | 2001-05-22 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
US5919937A (en) | 1997-10-29 | 1999-07-06 | Merck & Co., Inc. | Process for phosphodiesterase IV inhibitors |
JP2001523712A (en) | 1997-11-25 | 2001-11-27 | ワーナー−ランバート・カンパニー | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use |
ES2251121T3 (en) | 1997-12-24 | 2006-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | (4) -ARIL (PIPERIDIN-4-IL) AMINOBENZAMIDS THAT JOIN THE DELTA OPIOID RECEIVER. |
JP3542482B2 (en) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | 3-anilino-2-cycloalkenone derivatives |
ES2211175T3 (en) * | 1998-09-29 | 2004-07-01 | Wyeth Holdings Corporation | INHIBITORS OF TYPEOSIN KINASE PROTEINS BASED ON REPLACED 3-CYANOQUINOLINS. |
EP1157007A1 (en) | 1999-02-25 | 2001-11-28 | Merck Frosst Canada Inc. | Pde iv inhibiting compounds, compositions and methods of treatment |
US6180650B1 (en) | 1999-04-23 | 2001-01-30 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE 4 inhibitors |
US6200993B1 (en) | 1999-05-05 | 2001-03-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE4 inhibitors |
WO2000071129A1 (en) | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
MXPA02003436A (en) | 1999-10-07 | 2002-08-20 | Amgen Inc | Triazine kinase inhibitors. |
EP1235804A1 (en) * | 1999-11-27 | 2002-09-04 | Dong Wha Pharmaceutical Industrial Co. Ltd. | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives |
DE50011851D1 (en) | 1999-12-18 | 2006-01-19 | Wella Ag | 2-aminoalkyl-1,4-diaminobenzene derivatives and colorants containing these compounds |
MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
US6699890B2 (en) | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
AU2002303078B2 (en) | 2001-01-22 | 2007-08-30 | Memory Pharmaceuticals Corporation | Aniline derivatives useful as phosphodiesterase 4 inhibitors |
US7153871B2 (en) * | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
US20030149052A1 (en) | 2002-01-22 | 2003-08-07 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
NZ537724A (en) | 2002-07-19 | 2006-10-27 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
BR0315705A (en) | 2002-11-19 | 2005-09-06 | Memory Pharm Corp | Phosphodiesterase-4 Inhibitors |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
-
2003
- 2003-07-18 BR BR0313000-2A patent/BR0313000A/en not_active IP Right Cessation
- 2003-07-18 CN CNB03817233XA patent/CN100381425C/en not_active Expired - Fee Related
- 2003-07-18 JP JP2004523528A patent/JP2006502995A/en active Pending
- 2003-07-18 AU AU2003256601A patent/AU2003256601B2/en not_active Ceased
- 2003-07-18 MX MXPA05000825A patent/MXPA05000825A/en active IP Right Grant
- 2003-07-18 DE DE60325984T patent/DE60325984D1/en not_active Expired - Fee Related
- 2003-07-18 CN CNA2008101082889A patent/CN101423497A/en active Pending
- 2003-07-18 EP EP03765684A patent/EP1549619B1/en not_active Expired - Lifetime
- 2003-07-18 AT AT03765684T patent/ATE421505T1/en not_active IP Right Cessation
- 2003-07-18 RU RU2005104820/04A patent/RU2354648C2/en not_active IP Right Cessation
- 2003-07-18 ES ES03765684T patent/ES2323688T3/en not_active Expired - Lifetime
- 2003-07-18 NZ NZ537725A patent/NZ537725A/en unknown
- 2003-07-18 CA CA002492911A patent/CA2492911A1/en not_active Abandoned
- 2003-07-18 WO PCT/US2003/022401 patent/WO2004009557A1/en active Application Filing
-
2005
- 2005-01-05 IL IL16616405A patent/IL166164A0/en unknown
- 2005-01-17 ZA ZA200500436A patent/ZA200500436B/en unknown
- 2005-01-18 CO CO05003399A patent/CO5680420A2/en not_active Application Discontinuation
- 2005-01-26 HR HR20050082A patent/HRP20050082A2/en not_active Application Discontinuation
- 2005-02-18 NO NO20050871A patent/NO20050871L/en not_active Application Discontinuation
-
2006
- 2006-01-27 HK HK06101282A patent/HK1081194A1/en not_active IP Right Cessation
- 2006-12-21 US US11/642,592 patent/US7655802B2/en not_active Expired - Fee Related
-
2009
- 2009-12-17 US US12/640,607 patent/US20100093806A1/en not_active Abandoned
-
2010
- 2010-01-21 AU AU2010200233A patent/AU2010200233A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997000868A1 (en) * | 1995-06-21 | 1997-01-09 | Sanofi | 4-phenylaminothiazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
WO1997049702A1 (en) * | 1996-06-25 | 1997-12-31 | Pfizer Inc. | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
WO1998009961A1 (en) * | 1996-09-04 | 1998-03-12 | Pfizer Inc. | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
WO2000069841A2 (en) * | 1999-05-17 | 2000-11-23 | Bayer Aktiengesellschaft | Benzofuranylaminoalcohols |
JP2001011047A (en) * | 1999-06-28 | 2001-01-16 | Nikken Chem Co Ltd | Phosphodiesterase inhibitor |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518983B2 (en) | 2003-03-03 | 2013-08-27 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
US8017641B2 (en) | 2003-03-03 | 2011-09-13 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
JP2007519684A (en) * | 2004-02-02 | 2007-07-19 | ノバルティス アクチエンゲゼルシャフト | Coupling reactions useful in the preparation of (1H-tetrazol-5-yl) -biphenyl derivatives |
JP2008542332A (en) * | 2005-05-31 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pharmaceutical composition for the treatment of respiratory diseases |
US8039639B2 (en) | 2006-01-31 | 2011-10-18 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
US8044083B2 (en) | 2006-01-31 | 2011-10-25 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
US8436038B2 (en) | 2007-08-17 | 2013-05-07 | Lg Life Sciences Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
WO2009025478A1 (en) | 2007-08-17 | 2009-02-26 | Lg Life Sciences Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
US9000028B2 (en) | 2007-08-17 | 2015-04-07 | Lg Life Sciences Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
WO2014072881A1 (en) * | 2012-11-08 | 2014-05-15 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9617275B2 (en) | 2012-11-08 | 2017-04-11 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
RU2617842C2 (en) * | 2012-11-08 | 2017-04-28 | Пфайзер Инк. | Heteroaromatic compounds and their application as dopamine d1 ligants |
EP3323821A1 (en) * | 2012-11-08 | 2018-05-23 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
Also Published As
Publication number | Publication date |
---|---|
US20100093806A1 (en) | 2010-04-15 |
AU2010200233A1 (en) | 2010-02-11 |
HK1081194A1 (en) | 2006-05-12 |
US20070123570A1 (en) | 2007-05-31 |
JP2006502995A (en) | 2006-01-26 |
ZA200500436B (en) | 2006-07-26 |
RU2354648C2 (en) | 2009-05-10 |
CN101423497A (en) | 2009-05-06 |
IL166164A0 (en) | 2006-01-15 |
EP1549619A1 (en) | 2005-07-06 |
CA2492911A1 (en) | 2004-01-29 |
BR0313000A (en) | 2005-07-12 |
HRP20050082A2 (en) | 2005-06-30 |
ATE421505T1 (en) | 2009-02-15 |
DE60325984D1 (en) | 2009-03-12 |
NO20050871L (en) | 2005-02-18 |
US7655802B2 (en) | 2010-02-02 |
RU2005104820A (en) | 2005-10-10 |
ES2323688T3 (en) | 2009-07-23 |
NZ537725A (en) | 2006-08-31 |
AU2003256601B2 (en) | 2009-10-29 |
CN100381425C (en) | 2008-04-16 |
MXPA05000825A (en) | 2005-08-29 |
CN1668602A (en) | 2005-09-14 |
AU2003256601A1 (en) | 2004-02-09 |
EP1549619B1 (en) | 2009-01-21 |
CO5680420A2 (en) | 2006-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1692109B1 (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
US7655802B2 (en) | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs | |
US7700631B2 (en) | Phosphodiesterase 4 inhibitors | |
AU2002313673B2 (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | |
EP1435944B1 (en) | 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes | |
AU2002313673A1 (en) | Trifluoromethylpurines as phosphodiesterase 4 inhibitors | |
EP1353907A2 (en) | Phosphodiesterase 4 inhibitors | |
AU2002303078A1 (en) | Aniline derivatives useful as phosphodiesterase 4 inhibitors | |
WO2006135828A2 (en) | Trisubstituted amines as phosphodiesterase 4 inhibitors | |
US6699890B2 (en) | Phosphodiesterase 4 inhibitors | |
US7153871B2 (en) | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs | |
US7205320B2 (en) | Phosphodiesterase 4 inhibitors | |
NZ547469A (en) | 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
KR20050019902A (en) | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 76/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537725 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200500436 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492911 Country of ref document: CA Ref document number: 1020057000929 Country of ref document: KR Ref document number: 05003399 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000825 Country of ref document: MX Ref document number: 1-2005-500127 Country of ref document: PH Ref document number: 2003256601 Country of ref document: AU Ref document number: 2003817233X Country of ref document: CN Ref document number: 2004523528 Country of ref document: JP Ref document number: 2003765684 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20050082A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 2005104820 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057000929 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003765684 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501480 Country of ref document: PH |